Please use this identifier to cite or link to this item: https://doi.org/10.1155/2015/308574
Title: Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
Authors: Subhash, V.V
Yeo, M.S
Tan, W.L
Yong, W.P 
Keywords: antineoplastic agent
cancer vaccine
chimeric antigen receptor
cytotoxic T lymphocyte antigen 4
dendritic cell vaccine
durvalumab
immunomodulating agent
ipilimumab
mpdl 3280a
nivolumab
pembrolizumab
programmed death 1 ligand 1
T lymphocyte antigen
ticilimumab
tumor antigen
cancer vaccine
adaptive immunity
adoptive immunotherapy
adoptive transfer
cancer immunization
cancer immunotherapy
cytotoxic T lymphocyte
human
immune evasion
immune response
immune system
immunogenicity
immunosurveillance
innate immunity
multicenter study (topic)
natural killer cell
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
randomized controlled trial (topic)
Review
stomach cancer
T lymphocyte
tumor associated leukocyte
tumor microenvironment
clinical trial (topic)
immunity
immunological memory
immunological monitoring
immunology
immunotherapy
procedures
Stomach Neoplasms
Cancer Vaccines
Clinical Trials as Topic
Humans
Immune System Phenomena
Immunologic Memory
Immunotherapy
Monitoring, Immunologic
Stomach Neoplasms
Tumor Microenvironment
Issue Date: 2015
Citation: Subhash, V.V, Yeo, M.S, Tan, W.L, Yong, W.P (2015). Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research 2015 : 308574. ScholarBank@NUS Repository. https://doi.org/10.1155/2015/308574
Abstract: In cancer biology, cells and molecules that form the fundamental components of the tumor microenvironment play a major role in tumor initiation, and progression as well as responses to therapy. Therapeutic approaches that would enable and harness the immune system to target tumor cells mark the future of anticancer therapy as it could induce an immunological memory specific to the tumor type and further enhance tumor regression and relapse-free survival in cancer patients. Gastric cancer is one of the leading causes of cancer-related mortalities that has a modest survival benefit from existing treatment options. The advent of immunotherapy presents us with new approaches in gastric cancer treatment where adaptive cell therapies, cancer vaccines, and antibody therapies have all been used with promising outcomes. In this paper, we review the current advances and prospects in the gastric cancer immunotherapy. Special focus is laid on new strategies and clinical trials that attempt to enhance the efficacy of various immunotherapeutic modalities in gastric cancer. © 2015 Vinod Vijay Subhash et al.
Source Title: Journal of Immunology Research
URI: https://scholarbank.nus.edu.sg/handle/10635/176161
ISSN: 2314-8861
DOI: 10.1155/2015/308574
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2015_308574.pdf2.64 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.